Open AccessEffects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
Author(s) -
Kaneko Tetsuya,
Okamura Koichi,
Yonemoto Yukio,
Okura Chisa,
Suto Takahito,
Tachibana Masahiro,
Sakane Hideo,
Inoue Makoto,
Chikuda Hirotaka
Publication year - 2019
Publication title -
journal of experimental orthopaedics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 18
ISSN - 2197-1153
DOI - 10.1186/s40634-019-0211-7
Subject(s) - denosumab , medicine , bone mineral , osteoporosis , femoral neck , bone remodeling , rheumatoid arthritis , bisphosphonate , urology
Background To compare the efficacy of 12‐month denosumab treatment on bone mineral density (BMD) and bone turnover markers (BTMs) between treatment‐naïve osteoporosis patients with rheumatoid arthritis (RA) and those with previous bisphosphonate (BP) therapy. Methods A total of 36 RA patients with osteoporosis completed 12‐month follow‐up. Twenty‐five patients were osteoporotic treatment‐naïve (naïve group), and 11 patients were previously treated with BPs (switch group) (average 7.9 years). BMD and BTMs were measured before and 6 and 12 months after treatment. Results BTM levels were higher in the naïve group at baseline. However, the same level of suppression was achieved at 6 months in both groups. Spine BMD increased significantly in both groups. There was no significant difference in the mean percent changes of BMD of the spine (naïve group: 6.8 ± 0.8, switch group: 5.1 ± 1.5), femoral neck (2.9 ± 1.4, 2.9 ± 1.3), and total hip (1.7 ± 0.9, 1.4 ± 1.1) between these two groups at 12 months. Conclusions The effects of denosumab on BMD and BTMs of the switch group after long‐term BP treatment are comparable to those of the naïve group in RA patients. Thus, switching BPs to denosumab is one of the useful options to treat osteoporosis with RA.